Skip to content
lennox

Partner Treatment Library

GLP-1 & Weight Management

Tirzepatide/Cyanocobalamin

High-impact weekly appetite and weight-management support paired with vitamin B12.

Download evidence brief
Lennox Tirzepatide/Cyanocobalamin product vial
Common goals
Substantial average weight reduction when tirzepatide is paired with nutrition and physical-activity support.
Best program fit
May fit a structured weight-management offering with clinician-led screening and measurable follow-up.
Format
Injectable

Partner education guide

Where this may fit in an offering.

Substantial average weight reduction when tirzepatide is paired with nutrition and physical-activity support. Reduced hunger, earlier fullness, and improved control over food intake. A weekly formulation may offer a convenient, high-impact option for individuals who have not achieved durable results with lifestyle measures alone.

Educational business-planning summary. Potential benefits vary, are not guaranteed, and require individual-specific clinical review.

01 / Common goals

What people may want to understand.

Primary goals

Potential benefits and goals

  • Substantial average weight reduction when tirzepatide is paired with nutrition and physical-activity support.
  • Reduced hunger, earlier fullness, and improved control over food intake.
  • Potential improvements in waist size, blood sugar, blood pressure, physical function, and other obesity-related measures.

Program value

How it may support a program

  • A weekly formulation may offer a convenient, high-impact option for individuals who have not achieved durable results with lifestyle measures alone.
  • Added vitamin B12 may support individuals with a documented or clinically plausible deficiency.

Benefits are based primarily on standardized tirzepatide injection. Results vary, are not guaranteed, and the exact compounded vitamin blend requires separate clinical and quality review.

02 / Program fit

Program and operational considerations.

01Administration
Catalog format: Injectable. The prescribing clinician and dispensing pharmacy confirm the exact preparation, concentration, handling, and administration technique.
02Typical frequency
The studied tirzepatide regimen is once weekly with gradual escalation. The exact blend schedule is prescription-specific.
03Expected duration
Treatment is generally long term while benefit, tolerability, and clinical need continue.
04Practical advantages
A weekly formulation may offer a convenient, high-impact option for individuals who have not achieved durable results with lifestyle measures alone.

03 / Suitability considerations

Who may be considered.

Who may be considered

  • A carefully screened adult whose goals align with the potential benefits above and who understands that individual response varies.
  • An individual willing to complete clinician-directed baseline review, monitoring, and an outcome-based follow-up plan.

Qualification notes

  • A weekly formulation may offer a convenient, high-impact option for individuals who have not achieved durable results with lifestyle measures alone.
  • Strongest fit occurs when the exact formulation, route, source, contraindications, and measurable goals can be clearly documented.

04 / Safety & suitability

What must be screened before treatment.

01

Common or temporary

  • Nausea, diarrhea, constipation, vomiting, abdominal discomfort, reflux, and injection-site reactions are the most practical tolerability issues.
  • Symptoms are often most noticeable during dose escalation and may improve with time.

02

Serious or important

  • Important risks include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions, and serious hypersensitivity.
  • Low blood sugar is mainly a concern with insulin or insulin-releasing diabetes medicines.
  • The product carries a boxed warning based on thyroid C-cell tumors in rodents and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.

03

Avoid or use only with specialist input

  • Pregnancy or an active plan to become pregnant.
  • Personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2.
  • Prior serious hypersensitivity to the active drug or formulation ingredients.

04

Screening checklist

  • Confirm BMI, weight-related conditions, prior weight-care attempts, current medicines, and realistic long-term goals.
  • Review diabetes therapy, low-blood-sugar risk, kidney function when clinically indicated, and any history of pancreatitis or gallbladder disease.
  • Ask about severe delayed stomach emptying, persistent vomiting, planned surgery or deep sedation, pregnancy potential, and thyroid-cancer history.

05

When to refer

  • Urgent medical assessment is appropriate for severe or persistent abdominal pain, repeated vomiting with dehydration, suspected gallbladder disease, serious allergic reaction, or symptoms of marked hypoglycemia.
  • Complex diabetes regimens, active eating disorders, pregnancy, severe gastrointestinal disease, or uncertain endocrine cancer history require appropriately qualified medical review.

Safety information is not exhaustive. Prescribing, screening, dosing, monitoring, and emergency guidance must come from an appropriately licensed clinician and the exact product information.

What the research says · reviewed August 2026

Research and source context.

A large randomized trial supports tirzepatide, but not this exact compounded combination.

01 / Human research

The clearest clinical signal

Weekly tirzepatide caused about 15.0% to 20.9% mean weight loss at 72 weeks, versus 3.1% with placebo, in 2,539 adults. The exact tirzepatide+vitamin B12 mix has not been tested in a large trial.

02 / Real-world reports

What people describe

In about 12 detailed injection accounts sampled, reduced hunger sometimes began after the first dose but often took several weeks. Strong loss and no-effect stories both appeared.

Public personal accounts are unverified and cannot show how common an outcome is.

03 / Cautions

What deserves attention

Nausea, vomiting, diarrhea, constipation, belly pain, and reflux are common. Gallbladder disease and pancreatitis are uncommon but serious concerns. Dehydration can harm kidneys.

Does the research match this exact product?

Direct evidence is for the branded peptide alone at fixed trial doses, not this compounded vitamin blend.

Research and regulatory context

SURMOUNT-1 randomized 2,539 adults without diabetes. Mean weight change at 72 weeks was about -15.0%, -19.5%, and -20.9% across the 5 mg, 10 mg, and 15 mg groups versus -3.1% with placebo. The trial did not test the added vitamin.

Complete evidence briefClinical summary, safety notes, reported timing, regulatory context, and linked sources in one document.

Download the evidence briefPDF · larger type

Evidence and regulatory status can change. Confirm the current label, formulation, route, dose, pharmacy source, jurisdiction, and intended use before offering treatment.

Education before offering.

Treatment information is for education only. It is not medical advice. A licensed clinician will review your health and decide whether a treatment is appropriate for you. Eligibility and availability may vary.

Back to all treatments